Products Marketed low dose hormone replacement therapy
Marketed low dose hormone replacement therapy Pre-clinical Completed 💤 Quiet Menopause, Hormone Replacement Therapy, Post-Menopausal
Apr 1, 2005 → Jun 1, 2006
About Marketed low dose hormone replacement therapy Marketed low dose hormone replacement therapy is a pre-clinical stage product being developed by Novo Nordisk for Menopause. The current trial status is completed. This product is registered under clinical trial identifier NCT01487304. Target conditions include Menopause, Hormone Replacement Therapy, Post-Menopausal.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT01487304 Pre-clinical Completed Apr 1, 2005 Jun 1, 2006 Menopause
Product Company Stage Hype Score atomoxetine + placebo Eli Lilly Pre-clinical Fezolinetant + Placebo Astellas Pharma Phase 2 Cetrorelix Shionogi Pre-clinical Teriparatide (PTH 1-34) Eli Lilly Phase 2/3 Eszopiclone + Placebo Sumitomo Pharma Pre-clinical Comparator: placebo + Comparator: Estrace Merck Phase 1 esmirtazapine + Placebo Merck Phase 3 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) Novo Nordisk Pre-clinical 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Novo Nordisk Approved estradiol, 10 mcg + estradiol, 25 mcg + placebo Novo Nordisk Phase 3 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Novo Nordisk Phase 1 estradiol, 25 mcg Novo Nordisk Pre-clinical estradiol, 10 mcg Novo Nordisk Phase 3 estradiol, 10 mcg + estradiol, 25 mcg Novo Nordisk Phase 1 estradiol, 10 mcg Novo Nordisk Phase 3 2 mg estradiol / 1 mg norethisterone acetate (NETA) Novo Nordisk Phase 1 estradiol, 25 mcg Novo Nordisk Phase 3 estradiol, 25 mcg Novo Nordisk Phase 3 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo Novo Nordisk Phase 3 estradiol, 25 mcg + estradiol, 25 mcg Novo Nordisk Phase 1
Other Products from Novo Nordisk